Finance

Lists
DRREDDY:NSE
Dr Reddy's Laboratories Ltd
1 238,50 ₹
+0,74%
(+9,10) 1D
13 հոկ, 14:52:58 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for DRREDDY...
Open
1 230,90 ₹
High
1 250,70 ₹
Low
1 223,30 ₹
Mkt. cap
1,03 տրլն
Avg. vol.
1,82 մլն
Volume
2,23 մլն
Dividend
0,65%
Quarterly dividend
2,00 ₹
Ex-dividend date
10 հլս, 2026 թ.
P/E ratio
32,03
52-wk high
1 414,90 ₹
52-wk low
1 101,00 ₹
EPS
38,67 ₹
Shares outstanding
166,06 մլն
No. of employees
28 հզր
Open
1 230,90 ₹
High
1 250,70 ₹
Low
1 223,30 ₹
Mkt. cap
1,03 տրլն
Avg. vol.
1,82 մլն
Volume
2,23 մլն
Dividend
0,65%
Quarterly dividend
2,00 ₹
Ex-dividend date
10 հլս, 2026 թ.
P/E ratio
32,03
52-wk high
1 414,90 ₹
52-wk low
1 101,00 ₹
EPS
38,67 ₹
Shares outstanding
166,06 մլն
No. of employees
28 հզր
News stories
From web sources and news partners
www.marketscreener.com
www.marketscreener.com
·
14 ժամ առաջ
Dr. Reddy's Laboratories Shares Rise After BNP Paribas Upgrade
Profile
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. By 2007, Dr. Wikipedia
About Dr Reddy's Laboratories Ltd
CEOErez Israeli
Employees27,5 հզր
Founded1984
HeadquartersՀայդերաբադ, Անդհրա-Պրադեշ, Հնդկաստան
Sector-
Next call 10 օրից
հոկ 23, ուր, 16:00
Fiscal period
Q2 2027
- / 8,95 ₹
Revenue / Est. (INR)
- / 86,00 մլրդ
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
88,05 մլրդ
87,27 մլրդ
75,16 մլրդ
80,70 մլրդ
Cost of goods sold
39,91 մլրդ
40,46 մլրդ
41,47 մլրդ
43,16 մլրդ
Cost of revenue
39,91 մլրդ
40,46 մլրդ
41,47 մլրդ
43,16 մլրդ
Research and development expenses
6,20 մլրդ
6,15 մլրդ
5,46 մլրդ
5,77 մլրդ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
26,44 մլրդ
26,92 մլրդ
27,76 մլրդ
28,82 մլրդ
Operating expense
31,90 մլրդ
32,48 մլրդ
32,53 մլրդ
34,11 մլրդ
Total operating expenses
71,81 մլրդ
72,94 մլրդ
74,00 մլրդ
77,27 մլրդ
Operating income
16,24 մլրդ
14,33 մլրդ
1,16 մլրդ
3,43 մլրդ
Other non operating income
1,28 մլրդ
570,00 մլն
512,00 մլն
-
EBT including unusual items
18,35 մլրդ
15,43 մլրդ
1,99 մլրդ
5,53 մլրդ
EBT excluding unusual items
17,81 մլրդ
15,52 մլրդ
1,82 մլրդ
4,09 մլրդ
Income tax expense
4,08 մլրդ
3,53 մլրդ
-214,00 մլն
1,18 մլրդ
Effective tax rate
22,24%
22,90%
-10,75%
21,32%
Other operating expenses
-740,00 մլն
-591,00 մլն
-693,00 մլն
-477,00 մլն
Net income
14,37 մլրդ
12,10 մլրդ
2,20 մլրդ
4,44 մլրդ
Net profit margin
16,32%
13,86%
2,93%
5,50%
Earnings per share
17,87
14,77
5,74
5,33
Interest and investment income
912,00 մլն
796,00 մլն
890,00 մլն
999,00 մլն
Interest expense
-907,00 մլն
-944,00 մլն
-1,06 մլրդ
-1,26 մլրդ
Net interest expenses
5,00 մլն
-148,00 մլն
-167,00 մլն
-256,00 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
21,29 մլրդ
19,54 մլրդ
5,03 մլրդ
8,80 մլրդ
Gain or loss from assets sale
-308,00 մլն
-179,00 մլն
-2,10 մլրդ
-368,00 մլն
AI content may include mistakes. Learn more
Google Apps